Frazier Life Sciences — 2018 Investments
4 investments dated 2018 · listed companies and verified rows first · show all
Rare liver disease treatment company.
San Diego, US
Board seatPatrick HeronPatrick J. HeronPatrick Heron· per SEC Form D · $68.5M raise · filed Jan 2026
Seattle, US
Gregory R Roer(Executive Officer, Director)
Board seatNader Naini· per SEC Form D · $53M raise · filed Oct 2018
BiotechMenlo Park, US
Yigong Ge(Executive Officer, Director)Michael Savino(Executive Officer)David Socks(Director)
Board seatPatrick Heron· per SEC Form D · $10.7M raise · filed Jul 2018
BiotechDublin 1
Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.